| First Author | Moroi AJ | Year | 2019 |
| Journal | Blood Adv | Volume | 3 |
| Issue | 7 | Pages | 1154-1166 |
| PubMed ID | 30967391 | Mgi Jnum | J:294467 |
| Mgi Id | MGI:6456508 | Doi | 10.1182/bloodadvances.2018026328 |
| Citation | Moroi AJ, et al. (2019) Diacylglycerol kinase zeta is a negative regulator of GPVI-mediated platelet activation. Blood Adv 3(7):1154-1166 |
| abstractText | Diacylglycerol kinases (DGKs) are a family of enzymes that convert diacylglycerol (DAG) into phosphatidic acid (PA). The zeta isoform of DGK (DGKzeta) has been reported to inhibit T-cell responsiveness by downregulating intracellular levels of DAG. However, its role in platelet function remains undefined. In this study, we show that DGKzeta was expressed at significant levels in both platelets and megakaryocytes and that DGKzeta-knockout (DGKzeta-KO) mouse platelets were hyperreactive to glycoprotein VI (GPVI) agonists, as assessed by aggregation, spreading, granule secretion, and activation of relevant signal transduction molecules. In contrast, they were less responsive to thrombin. Platelets from DGKzeta-KO mice accumulated faster on collagen-coated microfluidic surfaces under conditions of arterial shear and stopped blood flow faster after ferric chloride-induced carotid artery injury. Other measures of hemostasis, as measured by tail bleeding time and rotational thromboelastometry analysis, were normal. Interestingly, DGKzeta deficiency led to increased GPVI expression on the platelet and megakaryocyte surfaces without affecting the expression of other platelet surface receptors. These results implicate DGKzeta as a novel negative regulator of GPVI-mediated platelet activation that plays an important role in regulating thrombus formation in vivo. |
